.png)
Circulating calprotectin - Versatile inflammation biomarker
Calprotectin (S100A8/A9 or MRP8/14) is a promising biomarker for neutrophil activation and inflammation in multiple infections and non-infections inflammatory conditions. Its fast increase in inflammation enables an early and sensitive detection of inflammation and risk stratification.1
If you want to learn more about this novel biomarker, please visit Gentian Diagnostic at booth #3644
Calprotectin (S100A8/A9) in inflammatory rheumatic diseases (IRDs)
Supporting early detection of inflammation
Calprotectin, a heterodimer composed of two calcium-binding proteins (S100A8/A9 or MRP8/14), is part of the S100 protein family and is abundantly expressed by white blood cells, particularly neutrophils. Large amounts of stored calprotectin are released from neutrophils during inflammation. This direct and fast upregulation in inflammation makes calprotectin a highly sensitive and early biomarker.
The concentrations of circulating calprotectin correspond to the degree of inflammation. Indications for its use have been reported in both infectious and non-infectious inflammatory conditions.1
A sensitive biomarker for disease activity
Calprotectin is emerging as valuable biomarker in several chronic inflammatory conditions, including rheumatic diseases like Rheumatoid Arthritis, Juvenile Idiopathic Arthritis and Still’s Disease. Locally released calprotectin enters the systemic circulation where it can be measured in serum and plasma, at levels proportional to joint inflammatory activity.2,3
- Direct marker of inflammatory activity
- Detect low grade and subclinical inflammation activity
- Monitoring of treatment and remission
- Risk marker for disease flares
Recommended in international clinical guidelines: ACR and EULAR/PReS
Both the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) in collaboration with the Paediatric Rheumatology European Society (PReS) have highlighted calprotectin as one of the new biomarkers strongly recommended in managing rheumatic diseases.
Namely, calprotectin (S100 protein as inflammatory marker) has been recommended in two first guidelines, regarding the diagnosis of Still’s disease (formerly known as systemic JIA and adult-onset Still’s disease) and the clinical workup up of IL-1 mediated autoinflammatory disease.
.png?width=1000&height=313&name=CTA(71).png)
Gentian Calprotectin GCAL® Immunoassay*
GCAL® is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) rapidly performed in only 10 minutes. As open channel assay it is available on a wide range of clinical chemistry platforms.
The assay is not cleared for use in the United States. The assay is CE-marked in compliance with IVDR 2017/746 (CE 0123).
Let’s connect at ADLM 2026
Interested in calprotectin’s clinical utility? Want to learn more about circulating calprotectin?
Meet us at booth #3644 at ADLM 2026. Book a meeting by sending an email to marketing@gentian.com or fill out the form below:
References:
- Pruenster M et al. S100A8/A9: From basic science to clinical application. Pharmacol Ther. 2016
- Wang Q et al. The Role of Calprotectin in Rheumatoid Arthritis. J Transl Int Med. 2019
- Ometto F et al. Calprotectin in rheumatic diseases. Exp Biol Med (Maywood). 2017
* GCAL® is CE-marked under the In Vitro Diagnostic Regulation (IVDR 2017/746, CE 0123). It is not cleared by the U.S. FDA and is not available for sale in the United States.
This material is provided for scientific and educational purposes only and is intended for international use. It does not constitute an offer to sell or distribute GCAL® in the United States.
This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances.
.png)